Cancer has long been recognized as a biologically heterogeneous disease, yet historically it has often been treated using relatively uniform therapeutic approaches.
Risk prediction models play a central role in modern preventive medicine. These models estimate the probability that an individual will develop a specific disease over a defined time period.
As a key component of precision medicine, microbiome science is reshaping our understanding of human biology and clinical care.
Biomarker-based monitoring is redefining how clinicians track disease progression in real time. This article explores how molecular, inflammatory, cancer, and cardiac biomarkers provide measurable insights into disease activity and treatment response. By enabling earlier detection of changes and more precise therapeutic adjustments, biomarker-driven monitoring is becoming a cornerstone of precision medicine and data-driven patient care.